3 Branded Generic, Rehydration and Eye Care Stocks With a Strong Future Roadmap: Alkem Laboratories, FDC and Dr. Agarwal's Health Care

Alkem Rs 5,205.00, P/E 28.43. FDC Rs 341.40, P/E 18.05. Dr. Agarwal's Health Care Rs 475.20, P/E 80.51. Closing prices of 12 Oct 2026.

Updated: 13 Oct 2026 • 9:22 am

Posted by:

3 Branded Generic, Rehydration and Eye Care Stocks With a Strong Future Roadmap: Alkem Laboratories, FDC and Dr. Agarwal's Health Care

Quick Answer

Branded generic, rehydration and eye care stocks with the clearest long-term roadmaps today include Alkem in branded generics and exports, FDC in oral rehydration products and eye and ear formulations and Dr. Agarwal's Health Care in eye care hospitals and clinics. FY26 revenue growth was 13.7% at Alkem, 3.9% at FDC and 20.9% at Dr. Agarwal's Health Care. P/E stands at 28.43 for Alkem (industry 37.59), 18.05 for FDC (industry 37.59) and 80.51 for Dr. Agarwal's Health Care (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Branded generic, rehydration and eye care stocks give investors exposure to medicines and eye care that patients and doctors rely on. Prescription growth, hospital additions and margins decide how much of that demand turns into profit.

This list covers three branded generic, rehydration and eye care stocks: Alkem Laboratories for branded generics and exports, FDC for oral rehydration products and eye and ear formulations and Dr. Agarwal's Health Care for eye care hospitals and clinics. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Branded Generic, Rehydration and Eye Care Stocks?

Branded generic, rehydration and eye care stocks are shares of companies that sell branded medicines or run specialty eye care centres. Results depend on prescription growth, hospital additions and margins, so growth and margins separate the stronger names.

Branded Generic, Rehydration and Eye Care Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three branded generic, rehydration and eye care stocks as of the 12 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Alkem Laboratories	5,205.00	62,663	28.43	37.59	16.66%	0.15
FDC	341.40	5,281	18.05	37.59	11.32%	0.01
Dr. Agarwal's Health Care	475.20	14,907	80.51	62.79	6.58%	0.53

Among healthcare stocks, Dr. Agarwal's Health Care trades at a premium to the industry P/E, while Alkem and FDC trade at a discount.

Why Do Branded Generic, Rehydration and Eye Care Stocks Have a Strong Roadmap in India?

Branded generic, rehydration and eye care stocks have a strong roadmap in India because rising health awareness, wider insurance cover and an ageing population keep lifting demand for medicines and specialty care. Three drivers stand out.

Prescription demand: Branded generics reach more patients through doctors.
Specialty care: Eye care needs rise with age and screen use.
Product depth: Trusted brands keep repeat demand steady.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore. Operating margin was 23.20% in FY26.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 28.43 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

FDC: Established Brands Drive the Pipeline

FDC's roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.

Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.

Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.

Dr. Agarwal's Health Care: A Growing Eye Care Network Drives the Pipeline

Dr. Agarwal's Health Care's roadmap rests on eye care hospitals and clinics across India and overseas, with a growing network of centres supporting patient volumes.

Revenue grew from Rs 713.78 crore in FY22 to Rs 2,124.52 crore in FY26, a 197.6% rise, and FY26 revenue was 20.9% higher than FY25. FY26 net profit rose 52.4% to Rs 168.14 crore. Over four years, net profit rose from Rs 43.16 crore in FY22 to Rs 168.14 crore. In Q1 FY27, revenue grew 23.9% to Rs 620.43 crore, and net profit rose 44.6% to Rs 55.02 crore. Operating margin was 29.95% in FY26.

Debt to equity is 0.53 and return on equity is 6.58%. FY26 operating cash flow was Rs 518.99 crore against capital expenditure of Rs 460.58 crore. At a P/E of 80.51 against an industry P/E of 62.79, the stock trades above its industry multiple.

What to watch: Return on equity of 6.58% is modest.

Best Branded Generic, Rehydration and Eye Care Stocks in India: Alkem vs FDC vs Dr. Agarwal's Health Care on Key Financials

Among the best branded generic, rehydration and eye care stocks in India, Alkem leads on return on equity; FDC leads on the lowest P/E and the lowest debt to equity; Dr. Agarwal's Health Care leads on FY26 revenue growth and FY26 operating margin. The table puts the numbers side by side.

Metric	Alkem	FDC	Dr. Agarwal's Health Care
FY26 revenue (Rs Cr)	15,295.62	2,284.45	2,124.52
FY26 revenue growth	13.7%	3.9%	20.9%
FY26 net profit (Rs Cr)	2,353.13	281.42	168.14
FY26 net profit growth	6.2%	5.5%	52.4%
FY26 operating profit margin	23.20%	20.21%	29.95%
Q1 FY27 revenue growth (YoY)	11.0%	4.6%	23.9%
Return on equity	16.66%	11.32%	6.58%
P/E ratio	28.43	18.05	80.51
Debt to equity	0.15	0.01	0.53
Dividend yield	1.01%	1.54%	0.00%
FY26 operating cash flow (Rs Cr)	1,963.03	200.45	518.99

Healthcare earnings follow prescription growth, hospital additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Branded Generic, Rehydration and Eye Care Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen branded generic, rehydration and eye care stocks and shortlist branded generic, rehydration and eye care stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and return on equity together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these branded generic, rehydration and eye care stocks

Risks to Consider Before Investing in Branded Generic, Rehydration and Eye Care Stocks

Pricing rules: Price controls can affect margins.
Competition: Rival brands and clinics can pressure growth.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Alkem, FDC and Dr. Agarwal's Health Care live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare stocks cover branded generics, rehydration products and eye care hospitals. Alkem leads on return on equity; FDC leads on the lowest P/E and the lowest debt to equity; Dr. Agarwal's Health Care leads on FY26 revenue growth and FY26 operating margin.

Across branded generic, rehydration and eye care stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the branded generic, rehydration and eye care stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Branded Generic, Rehydration and Eye Care Stocks

Which are the best branded generic, rehydration and eye care stocks in India with a strong roadmap?

Ans. Alkem Laboratories, FDC and Dr. Agarwal's Health Care stand out for their roadmaps in branded generics, rehydration products and eye care hospitals. FY26 revenue growth was 13.7% at Alkem, 3.9% at FDC and 20.9% at Dr. Agarwal's Health Care, and return on equity ranges from 6.58% to 16.66%.

Is Alkem Laboratories a good stock to buy now?

Ans. Alkem Laboratories has a debt to equity ratio of 0.15, a return on equity of 16.66% and a P/E of 28.43 against an industry P/E of 37.59. Valuation, growth and pricing rules move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Alkem, FDC and Dr. Agarwal's Health Care?

Ans. The P/E ratio is 28.43 for Alkem (industry 37.59), 18.05 for FDC (industry 37.59) and 80.51 for Dr. Agarwal's Health Care (industry 62.79). Only Dr. Agarwal's Health Care trades at or above the industry multiple.

Which of these branded generic, rehydration and eye care stocks has the highest return on equity?

Ans. Alkem Laboratories has the highest return on equity at 16.66%, followed by FDC at 11.32% and Dr. Agarwal's Health Care at 6.58%.

What are the risks of investing in branded generic, rehydration and eye care stocks?

Ans. The main risks are pricing rules, competition and quarterly trends. Price controls can affect margins.

How did Alkem, FDC and Dr. Agarwal's Health Care perform in Q1 FY27?

Ans. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. Dr. Agarwal's Health Care reported revenue of Rs 620.43 crore, up 23.9% year on year, and net profit rose 44.6% to Rs 55.02 crore.

Do branded generic, rehydration and eye care stocks pay dividends?

Ans. Alkem and FDC pay dividends. The dividend yield is 1.01% for Alkem and 1.54% for FDC, based on dividends declared for FY26.

How can I invest in branded generic, rehydration and eye care stocks in India?

Ans. You can buy branded generic, rehydration and eye care stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.